Prof. Ronald Stolk, MD PhD

Professor Ronald Stolk, head of the Department of Epidemiology, is an internationally established researcher in clinical epidemiology. Over the last years, his research focuses on life course epidemiology approaches of chronic diseases, based on cohort studies and gene-environment interactions. Life Course Epidemiology is a central aspect of the “Healthy Ageing” theme of the University Medical Center Groningen. Cohort studies and biobanks are the basis of Life Course Epidemiology, the principle study design to investigate Healthy Ageing. Over the last years, professor Stolk has become increasingly involved in the infrastructure for cohort studies at local, national and international level. These biobanks include both population based studies (LifeLines, GECKO, PIAMA, BioSHaRE) as well as clinical follow-up projects (PSI, Mondriaan). He is Chief Scientific Officer of the LifeLines project and will be acting as chairman at the LifeLines Symposium.


Erling Sundrehagen, MD PhD

Dr. Erling Sundrehagen is a medical doctor, a Master of Science in nuclear chemistry and has a PhD in immunology. He founded Axis Biochemicals ASA in 1985 and still serves as Chief Scientific Officer of Axis-shield PLC, as it is called nowadays. Dr. Sundrehagen has over 25 years of experience within clinical chemistry and biochemistry. He has received various international awards for his research in clinical chemistry and is experienced in international patenting.


At the LifeLines Symposium, he will be giving his
view on how a large biobank like LifeLines could
serve researchers in developing and validating
new biomarkers.

Joachim Struck, PhD

Dr. Joachim Struck holds a PhD in Biochemistry, and worked many years in the field of biomarker and assay development, amongst others for BRAHMS and since 2013 for Sphingotec. He is one of the inventors of procalcitonin as a marker for sepsis, and was strongly involved in research, release and acceptance into the market around this. In addition, he is inventor of many other biomarkers.

From his experience in this field, he will be giving his
view on how biobanks like LifeLines can be used for
biomarker development.

René Paulussen, PhD

René Paulussen, PhD in Biochemistry, has more than 25 years of experience in research institutes, contract research organizations, and pharmaceutical and biotechnology companies in Europe and North-America, from laboratory team leader to, most recently, Chief Operating Officer at Trans-Hit Biomarkers, Inc. in Montreal, Canada. Throughout his career he has been responsible for the development and validation of numerous biomarker tests (proteins, drugs, metabolites, DNA/RNA).

At the LifeLines Symposium, he will be paying
attention to ongoing developments in the field
of biomarkers, and the pivotal expectations for
biobanks and the biomarker market, specifically
in regard to sample quality.

Prof. Stephan Bakker, MD PhD

Professor Stephan Bakker is internist at the University Medical Center Groningen, where he is involved in cohort studies in renal transplant recipients, patients with diabetes and in the general population. He is program leader of the Groningen Institute for Organ Transplantation and head of the laboratories dedicated to the large epidemiological studies PREVEND and LifeLines. He has a long track record in the development, evaluation and application of biomarkers for nutrition and health in the general population and selected patient populations, and a long-standing experience with biobanking and the use of biobanks for assessment of biomarkers and performance of research.

He will be speaking about the UMCG experience with
large scale biobanking at the LifeLines Symposium,
especially on the role of the laboratory in analyses
regarding large-scale biobanking.

Bernard Dorhout, PhD

Bernard Dorhout studied pharmacy at the University of Groningen, where he also obtained his PhD degree in clinical chemistry (cum laude). He has more than 15 years of experience in the field of pharmacological research, from coordinating major heart failure mortality trials at Astra Pharmaceuticals in The Netherlands, via Director Project Management at Pharma Bio-Research (later PRA) in Zuidlaren to being the Director Clinical Pharmacology for the phase 1 unit of Xendo (later QPS Netherlands) in Groningen. Since 2010, he is Director of Research for the University Medical Center Groningen department of Cardiology, and Chief Executive Officer at G-Cure.


He will be speaking at the LifeLines Symposium
about his experience with the FDA audits on
handling of biological samples.

Prof. em. Hans Willems, PhD

Since 1972, professor emeritus Hans Willems has been working for the Radboud University Medical Center in Nijmegen. First as a biochemist, later as a clinical chemist and head of the department of Clinical Chemistry for 25 years. He conducted research on the diagnostics of inborn errors of metabolism and (pediatric) nephrology. The last ten years before his emeriti, he was working on the training of students of the Master Medicine and the Bachelor Biomedical Sciences. He also developed a new curriculum for clinical chemists. Since 2004, professor Willems was in charge of the laboratory aspects of the Radboud biobank and later on in the project String of Pearls.


At the LifeLines Symposium, he will be speaking
about the systematic quality assurance and sample
stability control in biobanking.

conference registration
 conference registration